4D Molecular Shares Fall After Filing For Fabry Disease Trial Amendment

• 4D Molecular Therapeutics Inc (NASDAQ: FDMT) said that in June, the company filed a protocol amendment with the FDA for the ongoing Phase 1/2 trial of 4D-310 for Fabry disease.

• The protocol amendment is intended to expand the eligible patient population, including the addition of female Fabry patients with symptomatic disease.

• SVB Securities cuts 4D Molecular to Market Perform from Outperform with a price target of $12, down from $28 after the Fabry update.

• The analyst feels this decision is an "unforced error," as it "introduces additional complexity into a population with an already small N and high inter-patient variability."

• Fabry disease is a rare inherited condition that affects enzymes that metabolize fat. Fat deposits then clog blood vessels and tissue.

• The inclusion of female patients in the phase 1/2 clinical trial was supported by clinical experience and a GLP toxicology study in female mice models.

• Related: 4D Molecular Shares Updated Data From Fabry Disease Trial.

• The company continues to expect to provide a clinical data update on 4D-310 in 1H of 2023.

• Cash, cash equivalents, and marketable securities were $261.6 million as of June 30, 2022. sufficient to fund operations into 1H of 2025.

• Five clinical-stage product candidates are on track for multiple clinical data updates in 2023.

• Price Action: FDMT shares are down 11.5% at $9.20 during the market session on the last check Friday.

Latest Ratings for FDMT

Date	Firm	Action	From	To
Jan 2022	SVB Leerink	Initiates Coverage On		Outperform
Jan 2021	B of A Securities	Initiates Coverage On		Buy
Jan 2021	Goldman Sachs	Initiates Coverage On		Neutral

View More Analyst Ratings for FDMT

View the Latest Analyst Ratings

See more from Benzinga

• MedTech Giant Abbott To Inject Over €400M In Ireland To Expand Production Of Glucose Monitoring Tech

• The Most Expensive Drug From Novartis Associated With Two Deaths: Report

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.